Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Class C beta-lactamases, also known as AmpC beta-lactamases or cephalosporinases, are enzymes produced by certain bacteria that confer resistance to a broad range of beta-lactam antibiotics. These enzymes hydrolyze the beta-lactam ring found in these antibiotics, rendering them ineffective against bacterial cell wall synthesis. They are serine-based enzymes and not inhibited by clavulanic acid or tazobactam. Avibactam can inhibit some class C β-lactamases. Common bacterial hosts include *Enterobacter cloacae*, *Citrobacter freundii*, *Serratia marcescens*, *Morganella morganii*, *Providencia* spp., *Pseudomonas aeruginosa*, and *Escherichia coli*.
Hydrolyzes the beta-lactam ring of beta-lactam antibiotics, preventing their binding to penicillin-binding proteins and inhibiting bacterial cell wall synthesis.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Beta Lactamase Enzyme Ambler Class C (AmpC).